In Advisory Opinion 20-02, the Office of Inspector General (OIG) approved certain lodging and travel assistance offered by a pharmaceutical manufacturer to patients being administered a drug manufactured by the pharmaceutical...more
2/29/2020
/ Advisory Opinions ,
Anti-Kickback Statute ,
Beneficiary Inducement ,
Black Box Warnings ,
Civil Monetary Penalty ,
Food and Drug Administration (FDA) ,
Free Health-Related Services ,
Medical Reimbursement ,
OIG ,
Patient Assistance Programs ,
Patients ,
Personalized Medicine ,
Pharmaceutical Industry ,
Prescription Drugs ,
REMS